Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.74 |
| ▸ | CA1 | P00915 | 2/20 | 0.74 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.74 |
| ▸ | CA12 | O43570 | 1/20 | 0.74 |
| ▸ | IDO1 | P14902 | 1/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | CA9 | Q16790 | 1/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25060935 | 0.91 | HDAC1 (0.75) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL1151494 | 0.89 | HDAC1 (0.63) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL8575405 | 0.89 | OGG1 (0.67) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL3550937 | 0.89 | HDAC6 (0.68) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL18313990 | 0.89 | HDAC6 (0.62) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL19631295 | 0.87 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL297618 | 0.87 | MEN1 (0.61) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL21694316 | 0.87 | HDAC6 (0.60) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL12687823 | 0.87 | OGG1 (0.71) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL2640636 | 0.87 | HDAC6 (0.60) | HDAC6HDAC1HDAC8HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981648-B2 | Method for the synthesis of 3-R-1,4,2-dioxazol-5-ones | TESLA, INC. (US) | 2024-05-14 | — | — | US | claimed |
| CN-114685808-B | Hydrogen bond associated pseudo three-dimensional titanium-carbon-based micro complex with one-dimensional pores opened, and preparation method and application thereof | 浙江工业大学 | 2023-02-28 | — | — | CN | claimed |
| US-20230029852-A1 | METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES | PANASONIC HOLDINGS CORPORATION (JP) | 2023-02-02 | — | — | US | claimed |
| CN-114685808-A | Hydrogen bond associated pseudo three-dimensional titanium-carbon-based micro complex with one-dimensional pores opened, and preparation method and application thereof | 浙江工业大学 | 2022-07-01 | — | — | CN | claimed |
| US-20250084551-A1 | CARBON DIOXIDE CONVERSION DEVICE AND CARBON DIOXIDE CONVERSION METHOD | Toshiba Energy Systems & Solutions Corporation (JP) | 2025-03-13 | — | — | US | disclosed |
| EP-4520855-A1 | CARBON DIOXIDE CONVERSION DEVICE AND CARBON DIOXIDE CONVERSION METHOD | Toshiba Energy Systems & Solutions Corporation (JP) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024031002-A1 | (2,4-DICHLOROPHENOXY)ACETIC ACID ANALOGS | CORTEVA AGRISCIENCE LLC (US) | 2024-02-08 | — | — | WO | disclosed |
| CN-114685808-B | Hydrogen bond associated pseudo three-dimensional titanium-carbon-based micro complex with one-dimensional pores opened, and preparation method and application thereof | 浙江工业大学 | 2023-02-28 | — | — | CN | disclosed |
| CN-114685808-B | Hydrogen bond associated pseudo three-dimensional titanium-carbon-based micro complex with one-dimensional pores opened, and preparation method and application thereof | 浙江工业大学 | 2023-02-28 | — | — | CN | disclosed |
| US-20230056785-A1 | GAS-STORING MATERIAL INCLUDING METAL/ORGANIC FRAMEWORK BONDED BY HYDROXAMIC ACID | RIKKYO EDUCATIONAL CORPORATION (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20230056785-A1 | GAS-STORING MATERIAL INCLUDING METAL/ORGANIC FRAMEWORK BONDED BY HYDROXAMIC ACID | RIKKYO EDUCATIONAL CORPORATION (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4074692-A1 | GAS-STORING MATERIAL INCLUDING METAL/ORGANIC FRAMEWORK BONDED BY HYDROXAMIC ACID | Rikkyo Educational Corporation (JP) | 2022-10-19 | — | — | EP | disclosed |
| EP-0594577-B1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHOD OF USE THEREOF | SLOAN KETTERING INST CANCER (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5840960-A | ANTITUMOR | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1998-11-24 | — | — | US | disclosed |
| US-5608108-A | ANTITUMOR AGENTS; LUNG, BLADDER, KIDNEY, BREAST, COLORECTAL | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0594577-A1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHOD OF USE THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5175191-A | Antitumor agents or anticancer agents | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-12-29 | — | — | US | disclosed |
| WO-1991008191-A1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHOD OF USE THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1991-06-13 | — | — | WO | disclosed |
| WO-1991000257-A1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1991-01-10 | — | — | WO | disclosed |
| US-3954718-A | Process for preparing polymers containing carbamoyl-hydroxamate groups and the resultant polymers | STANFORD RESEARCH INSTITUTE (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981648-B2 | Method for the synthesis of 3-R-1,4,2-dioxazol-5-ones | CYP4X1, DDO, CYP4B1 | HDAC6 1947/4885HDAC1 1595/4885HDAC8 2130/4885 |
| US-20230029852-A1 | METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES | CYP4X1, DDO, CYP4B1 | HDAC6 1947/4885HDAC1 1595/4885HDAC8 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.